Pfizer drives cancer research breakthroughs with supercritical fluid chromatography
23 Jan 2026
Supercritical fluid chromatography (SFC) is a separation technique that uses a supercritical fluid (most commonly carbon dioxide) as the mobile phase to efficiently purify compounds, offering faster processing, lower solvent consumption, and a more environmentally friendly alternative to traditional liquid chromatography (LC) methods. In this SelectScience interview, Jeff Elleraas, Principal Scientist at Pfizer’s Global Research and Development in La Jolla, California, shares insights into the role of SFC and how machine learning and AI are transforming chiral separations. Plus, discover Pfizer’s mission to tackle the toughest challenges in oncology research, accelerate medicinal chemistry innovations, and create greener, more efficient processes for developing novel cancer treatments.
Find out more information on Nexera UC here: https://www.shimadzu.com/an/products/liquid-chromatography/sfc/nexera-uc/index.html
About the company
Shimadzu Corporation
Shimadzu Corporation was founded in Kyoto, Japan in 1875 and has been supplying cutting-edge analytical and measuring instruments for a broad range of applications for over 140 years. Key markets include pharmaceuticals, life sciences, food & beverages, chemicals, petrochemicals, environmental, material science, and forensics/toxicology. Products include chromatographs (HPLC/UHPLC/SFC, GC), mass spectrometers (GC-MS/MS, LC-MS/MS, MALDI, ICP-MS), spectrophotometers (FT-IR, Fluorescence, UV-VIS-NIR), atomic spectrometers (AA, ICP), X-ray spectrometers (ED-XRF, XRD, XRF), thermal analyzers, Total Organic Carbon (TOC) analyzers, particle size analyzers, material testing machines, and balances, etc.
